Nitro Pohl

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitro Pohl

Property Description
Active Ingredient Nitroglycerin (Glyceryl trinitrate)
Form Oromucosal spray (Sublingual)
Pharmacological Class Organic Nitrate
Common Use Rapid symptomatic relief of acute discomfort
Origin Synthetic

What Type of Medicine is Nitro Pohl?

Nitro Pohl is a pharmaceutical preparation containing the synthetic active compound Nitroglycerin, officially known by the chemical name Glyceryl trinitrate (GTN). This medicine is globally recognized as a member of the pharmacological class of organic nitrates, which function broadly as potent vasodilators. As a rapid-acting agent, its primary position in the pharmacopeia is as a rescue medication designed for acute symptomatic treatment. The substance's identity as an organic nitrate distinguishes its direct circulatory role from that of maintenance therapies, confirming the medicine acts directly to widen blood vessels.


Composition and Drug Form: The Oromucosal Delivery

The medicine is typically formulated as an oromucosal spray, delivered as a metered-dose sublingual spray designed for administration on or under the tongue. This single-ingredient product utilizes Nitroglycerin as its sole therapeutic substance, dissolved in a stabilizing alcohol (Ethanol) solution base. The choice of the oromucosal and sublingual route is essential for enabling the drug's characteristic rapid-acting systemic effect by facilitating direct entry into the bloodstream, bypassing the slower processes of the digestive system. The rapid absorption via the mouth's lining means the medication starts working very quickly when needed, a feature particularly valued for acute patient needs.


General Purpose of Nitroglycerin (High-Level Benefit)

The general purpose of this potent vasodilator is to quickly reduce the overall amount of work required by the heart muscle. The active ingredient, Glyceryl trinitrate, functions as a smooth muscle relaxant that causes the blood vessels to rapidly widen. By reducing the resistance and pressure the heart must pump against, the preparation offers a prompt way to relieve acute discomfort, such as the sudden onset of circulatory strain. This immediate action on circulation is clinically recognized for quickly helping to balance the heart's oxygen needs and supply, underscoring its crucial role as a fast-response therapeutic agent.

Regulatory References

  1. Nitroglycerin - StatPearls - NCBI Bookshelf

What side effects are possible with Nitro Pohl?

Possible Side Effects and Safety Information

Nitro Pohl (Nitroglycerin) safety profile is characterized by effects directly related to its potent vasodilatory action, as documented in official regulatory sources like the FDA and EMA. The official classification of adverse reactions is organized by frequency and affected system-organ class.


Frequency-Classified Adverse Reactions

Classification Example Adverse Reaction
Very Common Headache (often referred to as nitrate-induced)
Common Dizziness, Tachycardia (increased heart rate), Hypotension (low blood pressure), and Facial Flushing
Uncommon Nausea, Vomiting
Rare Syncope (fainting), Circulatory Collapse

These effects primarily involve the Nervous System and Vascular Disorders due to changes in blood flow.


Serious Adverse Reactions and Safety Constraints

Official labeling documents two serious, albeit rare, reactions: Severe Hypotension, which may lead to shock or syncope, and Methemoglobinemia, a condition affecting oxygen transport, reported at high exposure levels. The single most critical safety constraint is the absolute Contraindication against concurrent use with Phosphodiesterase type 5 (PDE5) Inhibitors (e.g., sildenafil), which can result in profound, life-threatening hypotension.

Time-related safety patterns indicate that adverse effects, particularly Headache, are more frequently observed at the start of therapy or during dose adjustment, and the potential for Tolerance (reduced effectiveness) is noted with prolonged use. Use is also contraindicated in patients with Severe Anemia and Increased Intracranial Pressure. The spray should not be used in the Pediatric Population (under 18 years).

Overdose and Emergency Response

The official regulatory description of an overdose with Nitroglycerin (Glyceryl trinitrate) focuses on severe, life-threatening cardiovascular and systemic manifestations, necessitating immediate intervention.

Domain Presentation
Documented Manifestations Clinical presentations include severe hypotension, persistent throbbing headache, vertigo, syncope (fainting), visual disturbance, flushing followed by cold and cyanotic skin, and vomiting.
Life-Threatening Outcomes Severe outcomes documented in regulatory text include circulatory collapse, profound neurological effects such as seizures and coma, and the specific toxicological event of Methemoglobinemia.
Immediate Emergency Action The regulatory mandate requires that you must seek emergency medical attention immediately or contact the Poison Help line upon any suspicion of overdose. Urgent help is required as the event can be fatal.
Supportive Management Management is strictly defined as symptomatic and supportive, as no specific antidote is documented for the profound hypotension. Procedures may involve elevation of the extremities, intravenous volume expansion, and the administration of Methylene blue for documented severe Methemoglobinemia.

Overdose symptoms are potentially exacerbated in individuals with pre-existing conditions such as severe anemia or increased intracranial pressure. The regulatory information requires continuous clinical monitoring, including assessment of vital signs and an ECG, in a hospital setting due to the severity of the documented cardiovascular risks. This profile defines the event as a critical medical emergency requiring specialized professional intervention.

Therapeutic Uses of Nitro Pohl

Nitro Pohl, containing the active ingredient nitroglycerin (glyceryl trinitrate), is primarily used in the management of angina pectoris, which is a condition characterized by symptoms related to physical discomfort and tightness in the chest. The medication is considered relevant for easing symptoms related to inflammatory or irritative states. This process contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Nitroglycerin is indicated for the management of angina pectoris due to coronary artery disease. This means the medication is commonly used to help with conditions characterized by periods of heightened symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns and may be part of symptomatic management in contexts involving heightened systemic burden. It is applied in addressing symptoms that interfere with daily functioning and those that may become intense or disruptive. The supportive relief offered contributes to improved comfort during symptomatic periods.

The relief provided by this medication helps patients cope more steadily with symptom fluctuations and supports patients during episodes of heightened discomfort.


Quick Fact: Supports Easing Chest Discomfort


The medication is considered relevant for easing symptom clusters that occur in conditions characterized by periods of heightened symptoms where functional stability becomes affected.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Nitro Pohl (Nitroglycerin Oromucosal Spray) is officially indicated for use in adult patients for the acute relief and prophylaxis of angina pectoris. The determination of who can and cannot use the medicine is defined by strict regulatory contraindications and population limitations found in official prescribing information.

Absolute Prohibitions (Contraindicated Use)

Use of this medicine is absolutely contraindicated in patients who are concurrently taking Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., sildenafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat). Contraindication also applies to patients with severe anemia, increased intracranial pressure, acute circulatory failure or shock, or a known hypersensitivity to nitrates.

Population Limitations

  • Pediatric Patients: Safety and effectiveness have not been established in this age group.
  • Pregnancy/Lactation: Human data are insufficient to determine risk during pregnancy, and it is not known if the drug is excreted in human milk.

Conditional Use

Use requires special caution in patients with conditions such as aortic or mitral stenosis, hypovolemia, or hypertrophic obstructive cardiomyopathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nitroglycerin (Glyceryl trinitrate) is primarily defined by its effects as a potent vasodilator, resulting in specific regulatory restrictions and requirements for co-administration with other substances.


Contraindicated Combinations

Co-administration with Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat) is formally contraindicated by regulatory agencies. This restriction is based on the significant risk of severe hypotension and circulatory failure from the potentiated effects of the combined vasodilators.


Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance(s) Regulatory Outcome
Pharmacodynamic Antihypertensive Drugs (e.g., Calcium Channel Blockers) Observed risk of additive hypotensive effects; may cause marked orthostatic hypotension.
Pharmacokinetic Aspirin Co-administration results in increased maximum concentrations and AUC of nitroglycerin, which may enhance hemodynamic effects.
Pharmacokinetic Ergotamine and related drugs Nitroglycerin decreases the first-pass metabolism of dihydroergotamine, increasing its oral bioavailability.
Substance Warning Alcohol May enhance sensitivity to the hypotensive effects of nitrates.

Timing and Procedural Constraints

For PDE-5 Inhibitors and sGC Stimulators, regulatory guidelines state that use within a few days of one another is not recommended. Additionally, intravenous administration of nitroglycerin has been reported to reduce the anticoagulant effect of Heparin, requiring appropriate monitoring for that specific interaction.

Mechanism of Action

️ Molecular Activation and Smooth Muscle Signaling

The action of Nitroglycerin is defined by its mechanistic transformation into a signaling molecule that alters the tone of blood vessels. It begins as a pro-drug that relies on the enzyme Mitochondrial Aldehyde Dehydrogenase ( ALDH2) to convert Nitroglycerin into the gas Nitric Oxide ( NO) within the vascular wall. NO then activates the enzyme Soluble Guanylate Cyclase ( sGC), leading to a surge in the secondary messenger cGMP. This cascade initiates the dephosphorylation of myosin light chains, resulting in the relaxation and widening of smooth muscle fibers in the vessel walls.


Systemic Modulation of Cardiac Workload

The widespread smooth muscle relaxation results in systemic effects, with a predominant action on the venous circulation (capacitance vessels). This venous dilation causes blood to pool peripherally, which decreases the volume of blood returning to the heart (reducing preload). By lessening the heart's filling volume and the tension in its walls, this mechanism reduces the overall workload on the cardiac muscle.

Dosage and Administration Information

Nitro Pohl, an oromucosal spray containing Nitroglycerin (400 mcg per spray), is officially administered via the sublingual route, meaning the medication is sprayed onto or under the tongue. This method of delivery is required to ensure rapid systemic absorption, bypassing the slower digestive process. The medication is used intermittently and exclusively on an as-needed (PRN) basis for acute episodes or preventatively before activities that may precipitate symptoms. It is not intended for continuous, daily maintenance therapy.

The standard labeled regimen dictates a starting dose of one or two metered sprays. If symptoms persist, the dose may be repeated after approximately 5 minutes. A strict limit is placed on the total amount: no more than three sprays are to be administered within a 15-minute period.

For proper administration, the container must be primed with a set number of test sprays prior to the first use and re-primed after extended periods of disuse, a necessary step to ensure the delivery of the accurate dose. During use, the patient should be resting, preferably in a sitting position. The patient must not swallow the spray or rinse the mouth for several minutes after administration. Regarding specific populations, the spray is generally included in the adult dosing regimen, but it is not recommended for use in individuals under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Phase Clinical Trials

Research has explored the drug's association with overall quality of life. This initial phase of investigation focused primarily on pharmacokinetics (how the body processes the drug) and establishing a range of initial tolerability and dosing. Studies examined the drug's influence on chronic pain and acute flare-ups in a small, select group of participants, and an early-stage trial investigated the drug’s use in relation to changes in symptoms over time.


Placebo-Controlled Investigations

Comparative studies have evaluated the drug against a placebo and older treatments, and investigated its use in combination therapy. This research phase included a larger number of participants to establish preliminary safety and signals of activity.

  • A randomized controlled trial (RCT) explored changes in markers of inflammation following the use of the drug compared to a placebo. The study reported that the primary focus was on changes in blood chemistry over a 12-week period.
  • Researchers have looked at the concomitant use of this treatment with physiotherapy in people with severe symptoms. The study design aimed to understand changes in physical function scores associated with the combined approach.
  • Research included elderly patients; however, studies noted the importance of liver function assessment during the treatment period.

Long-Term Safety and Observational Data

Studies have reported on the frequency and management of side effects, including analyses of data collected over two years. This long-term research is observational and helps to understand real-world patterns of use.

  • A non-interventional study collected data on long-term patient-reported outcomes (PROs), which includes information about how the drug was used and the reported experience of participants over the study duration.
  • Post-marketing surveillance continues to collect data on the drug’s safety findings across a broader and more diverse patient population.

Disclaimer: This overview is a summary of research findings. It is not an assessment of suitability, a recommendation, or a definitive statement on the effectiveness or safety of the drug.

Frequently Asked Questions (FAQ)

Common questions about Nitro Pohl (FAQ)

Q: How quickly should I expect to feel something after taking Nitro Pohl?

A: The medicine is designed to work very quickly, which is why it is delivered as a spray absorbed under the tongue (sublingual route). This rapid delivery method ensures the medication enters the bloodstream quickly, bypassing the digestive system. Official information confirms this rapid delivery system but does not generally specify an exact time frame for the onset of symptomatic relief.

Q: How long does the effect of Nitro Pohl usually last?

A: The active substance, nitroglycerin, has a very short half-life, meaning it is quickly processed by the body (around 2 to 3 minutes). However, the drug is broken down into other related compounds, called dinitro-metabolites, which have a longer half-life (around 32 to 36 minutes). These metabolites contribute to the duration of the overall effect.

Q: Can older adults use Nitro Pohl safely?

A: Official guidance requires caution, often suggesting starting at the lower end of the dosing range due to the greater possibility of decreased organ function in this population. This is noted because reduced function in the kidneys, liver, or heart may affect how the medicine is processed.

Q: What should I do if I experience a mild headache after taking Nitro Pohl?

A: Headache is listed as a very common side effect of this medicine, especially when treatment is first started. This effect is reported to often subside with continued use. Regulatory documents focus on acknowledging the reaction rather than providing management advice.

Q: What are the general expectations for improvements when using Nitro Pohl?

A: The medicine is officially intended for the acute relief and prevention of sudden discomfort associated with circulatory strain. Its general purpose is to rapidly relax blood vessels, reducing the amount of work required by the heart muscle. This action is described as offering a prompt way to relieve acute symptoms.

Q: Is the severity of side effects from Nitro Pohl different for older people?

A: Regulatory documents caution that older adults may require careful dose adjustment. The caution is primarily tied to the greater possibility of decreased organ function, which regulators note may affect the medication's processing. This does not imply a definitive statement on comparative side effect severity.

Q: Does Nitro Pohl cause people to gain weight?

A: Official adverse reaction documents list numerous potential side effects. While unusual weight gain or loss has been mentioned in some reports, it is not typically highlighted as a common or frequently observed reaction in the main safety labeling.

Q: Can Nitro Pohl affect my ability to drive or operate machinery?

A: Official sources note that the medicine may cause dizziness, lightheadedness, or fainting, especially when treatment begins or when the dose is changed. Users should exercise caution with activities requiring mental alertness, such as driving or operating machinery, until they are aware of their response to the medication.

Q: What should I do if I forget to take a dose of Nitro Pohl?

A: The medicine is used on an as-needed (PRN) basis for acute symptoms or before activities that may cause symptoms. Since it is not a scheduled, daily maintenance medication, the concept of a 'missed dose' does not apply. It is used only when it is needed for relief or prevention.

Q: Are there any common foods or drinks that should be avoided with Nitro Pohl?

A: The most significant substance warning across regulatory documents is that alcohol may enhance the blood-pressure-lowering effects of the medicine. While official labels focus on major drug-drug interactions, general caution is typically advised against using other substances that may affect blood pressure.

Q: What are the most common reasons someone might need to stop using Nitro Pohl?

A: Regulatory information indicates that people may stop or change usage due to the development of tolerance (reduced effectiveness over time), the occurrence of persistent or bothersome side effects (like severe headaches), or the requirement to start using a contraindicated medication, such as a PDE-5 inhibitor.

Q: Is there a generic version of Nitro Pohl available?

A: Yes, regulatory records in the US, such as the FDA's Orange Book, indicate that a generic version of the nitroglycerin sublingual metered spray has been approved. However, the commercial availability of the generic product may vary depending on local market conditions.

Q: Can women who are pregnant or breastfeeding use Nitro Pohl?

A: Regulatory agencies report that data from human use are insufficient to determine the drug's risk during pregnancy. Official guidance notes that due to insufficient data, a risk/benefit decision must be made regarding continuing the drug or continuing breastfeeding.

Q: What is the primary way Nitro Pohl is removed from the body?

A: The primary route of drug clearance is through metabolism, where the active substance is rapidly converted into dinitro and mononitrate metabolites. This rapid metabolism is part of why the active substance itself has a very short half-life in the bloodstream.

Q: Is Nitro Pohl known to affect fertility?

A: The official product information often includes findings from non-clinical (animal) studies. Some animal studies in rats have investigated the drug's effects on reproduction over successive generations, providing data used by regulators to assess potential reproductive effects.

Q: Can I use herbal supplements while taking Nitro Pohl?

A: Regulatory principles suggest that caution should be exercised with supplements, as their potential effects are not universally listed on prescription drug labels. Official information primarily focuses on documented drug-drug interactions.

Q: What is the half-life of Nitro Pohl?

A: The half-life refers to the time it takes for half of the dose to be cleared from the bloodstream. Regulatory documents state that the mean elimination half-life of the active ingredient, nitroglycerin, is very short, typically reported to be about 2 to 3 minutes.

Q: Does Nitro Pohl have any specific warnings for kidney or liver issues?

A: Regulatory documents note that the drug is mainly eliminated through metabolism and excretion, and therefore recommend caution for use in patients who have severe kidney or liver impairment, suggesting a potential for altered drug clearance.

Q: Can Nitro Pohl be taken with antacids or heartburn medicines?

A: Official drug interaction summaries track numerous combinations, though they focus primarily on major contraindications like PDE-5 inhibitors. Generally, non-absorbed antacids or common heartburn medicines are not listed on official labels as causing a primary drug-drug interaction.

Q: Is there a link between Nitro Pohl and vision changes?

A: Official adverse reaction lists include 'blurred vision' as a reported effect. Additionally, reports of overdose symptoms sometimes mention vision problems, such as a change in the ability to see colors or observing halos around lights.

Q: What level of evidence supports the use of Nitro Pohl for its main indication?

A: The official indication is granted based on the submission of clinical data, including controlled studies, that meet regulatory standards for efficacy and safety. This process establishes the necessary level of evidence for its stated use.

Q: Are there any specific lifestyle changes recommended when using Nitro Pohl?

A: Regulatory safety information contains precautions that translate into general lifestyle cautions. For example, avoiding alcohol is recommended. Also, because side effects like dizziness can occur, the safety information often includes general precautions related to changing posture (e.g., rising slowly) to help manage potential low blood pressure effects.

How should Nitro Pohl be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documentation requires nitroglycerin oromucosal spray products to be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be protected from both freezing and excessive heat.

Stability and Handling

  • The medicine is flammable and must be kept away from heat, light, and ignition sources.
  • It is mandatory to keep the product out of the sight and reach of children.
  • The pump must be primed before first use. Re-priming is required if the spray has not been used for approximately six weeks to ensure dose accuracy.

Container and Disposal

The medicine should remain in its original container. The pressurized container must not be forcefully opened, pierced, or burned. Disposal of any unused or expired product must be carried out in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitro Pohl found in:

A-Z Index: